Lantheus Holdings Inc（LNTH）股票分析LNTHLantheus Holdings Inc

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Lantheus Holdings Inc is currently trading at $99.80, which is below the analyst price target of $102.50, indicating a potential upside of about 2.5%. However, the RSI is at 38.57, suggesting that the stock is approaching oversold territory, which could indicate a potential rebound. The recent FDA approval of Bravnetsa is a positive catalyst, but the acquisition by Curium for $102.50 per share raises concerns about the stock's future performance as it may no longer trade on fundamentals. The main risk is the hedge fund selling activity, which increased by 2127.26% over the last quarter, indicating a lack of confidence among institutional investors. Therefore, while there are some positive indicators, the significant insider selling and the downgrade of analyst ratings suggest that it may be prudent to hold rather than buy at this time.

4 analysts cover LNTH: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 82.17.